Articles scientifiques

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Auteurs : Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, Mcfadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber Rd, Perez EA
Année : 2016
Journal : J Clin Oncol
Volume : 34(10)
Pages : 1034-42

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.

Auteurs : Bottai G, Raschioni C, Losurdo A, Di Tommaso L, Tinterri C, Torrisi R, Reis-Filho JS, Roncalli M, Sotiriou C, Santoro A, Mantovani A, Loi S, Santarpia L
Année : 2016
Journal : Breast Cancer Res
Volume : 18
Pages : 121

New generation of breast cancer clinical trials implementing molecular profiling.

Auteurs : Zardavas D, Piccart-Gebhart M
Année : 2016
Journal : Cancer Biol Med
Volume : 13
Pages : 226-35

Nasopharyngeal adenoid cystic carcinoma, a rare but highly challenging disease with unmet therapeutic needs: A case-report and review of the literature].

Auteurs : Afani L, Errihani H, Benchafai I, Lalami Y
Année : 2016
Journal : Cancer Radiother
Volume : 20(5)
Pages : 400-4

The genomic landscape of breast cancer and its interaction with host immunity.

Auteurs : Luen S, Virassamy B, Savas P, Salgado R, Loi S
Année : 2016
Journal : Breast
Volume : 29
Pages : 241-50

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.

Auteurs : Agarwal N, Machiels JP, Suárez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M
Année : 2016
Journal : Oncologist
Volume : 21(5)
Pages : 535-6

Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future

Auteurs : Klastersky J, Paesmans M, Aoun M, Georgala A, Loizidou A, Lalami Y, Dal Lago L
Année : 2016
Journal : World J Clin Infect Dis
Volume : 6(3)
Pages : 37-60

Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy.

Auteurs : Tabchi S, Kourie HR, Kattan J
Année : 2016
Journal : Invest New Drugs
Volume : 34(6)
Pages : 794-6

Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases.

Auteurs : Lucidi V, Hendlisz A, Van Laethem JL, Donckier V
Année : 2016
Journal : World J Gastroenterol
Volume : 22
Pages : 3937-44

Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?

Auteurs : Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, DHondt L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N
Année : 2016
Journal : European urology supplements
Volume : 15(3)
Pages : -

Are virus-induced cancers more sensitive to checkpoint inhibitors?

Auteurs : Kanaan H, Kourie HR, Awada A
Année : 2016
Journal : Future Oncol
Volume : 12(23)
Pages : 2665-68

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

Auteurs : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart-Gebhart M
Année : 2016
Journal : Ann Oncol
Volume : 27
Pages : 205-207

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Auteurs : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Année : 2016
Journal : Eur J Cancer
Volume : 60
Pages : 117-124

Immune checkpoint inhibitors renal side effects and management.

Auteurs : Rassy EE, Kourie HR, Rizkallah J, Karak FE, Hanna C, Chelala DN, Ghosn M
Année : 2016
Journal : Immunotherapy
Volume : 8
Pages : 1417-1425

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.

Auteurs : Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, Dhont L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N
Année : 2016
Journal : Urol Oncol
Volume : 34(6)
Pages : 254.e7-254.e13

Guidance for the prevention and treatment of venous thromboembolism in cancer patients

Auteurs : Awada A, Baurain JF, Clement P, Hainaut P, Holbrechts S, Hougardy JM, Jochmans K, Mathieu V, Mebis J, Strijbos MH, Vulsteke C, Verheij M
Année : 2016
Journal : Belgian J Medical Oncology
Volume : 7(6)
Pages : 217-23

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Auteurs : Cardoso F, Vant Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, Delorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart-Gebhart M
Année : 2016
Journal : N Engl J Med
Volume : 375(8)
Pages : 717-29

Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.

Auteurs : Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, Dhoore A, Iserentant H, Hendlisz A, Mazzone M
Année : 2016
Journal : Gut
Volume : 65(6)
Pages : 990-1000

Too little benefit for too much toxicity: rethinking the adjuvant development model in colon cancer.

Auteurs : Hendlisz A, Bleiberg H
Année : 2016
Journal : Curr Opin Oncol
Volume : 28(4)
Pages : 345-7

Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.

Auteurs : Habre M, Habre SB, Kourie HR
Année : 2016
Journal : Immunotherapy
Volume : 8
Pages : 1437-1446